MultiCell Technologies Inc. engages in the development and commercialization of breakthrough therapeutics, and has a portfolio of new drug candidates and patented drug development technology platforms. The company today announced it has received European patent covering (EP 1539819B1) for its therapeutic candidates for the treatment of cancer.

“We are very pleased that the European Patent Office has decided to grant us a patent covering our novel compositions and method for the treatment of cancer as well as for the treatment of infectious disease,” Jerry Newmin, chairman and CEO of MultiCell Technologies stated in the press release. “Our technology uses the antibody molecule as a platform to better present a peptide to immune cells thereby increasing the overall immune response to the peptide.”

In addition to today’s announcement, MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), one U.S. patent application (U.S. 2006/0019387A1), and several corresponding issued and pending foreign patents and patent applications related to the isolation and differentiation of liver stem cells.

MultiCell’s intellectual property portfolio consists of novel drug development platform technologies and new drug candidates that the company leverages to develop new therapeutic candidates. The company focuses its efforts to develop treatment for diseases such as multiple sclerosis, type-1 diabetes and virus infections.